Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cypress Eyeing $200-400 Mil. Prosorba Sales Based On 1-2% Of RA Market

This article was originally published in The Gray Sheet

Executive Summary

Cypress Bioscience expects its Prosorba column for treatment of rheumatoid arthritis to be a $200-400 mil. product by 2003, the company said following FDA's premarket approval of the device March 16. The PMA was submitted last July.
Advertisement

Related Content

Cypress Bioscience Prosorba Rheumatoid Arthritis Trial Gets HCFA Nod
Cypress Bioscience Prosorba Rheumatoid Arthritis Trial Gets HCFA Nod
HCFA Commits To Coverage Decision On Prosorba For Rheumatoid Arthritis
HCFA Commits To Coverage Decision On Prosorba For Rheumatoid Arthritis
Advertisement
UsernamePublicRestriction

Register

MT011490

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel